Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 12:16:17562872241297579.
doi: 10.1177/17562872241297579. eCollection 2024 Jan-Dec.

Prognostic factors and treatment choice for stage IV, low-volume metastasis hormone-sensitive prostate cancer: cross-sectional study of real-world data

Mohamed Ibrahim Elewaily  1   2 , Marina Campione  3 , Mona Ali Hassan  4 , Shobana Anpalakhan  2 , Naoko Atsumi  4 , Benjamin Smalley  4   2 , Anza Ashraf  4 , Joanna Gale  4 , Akash Maniam  4 , Giuseppe Luigi Banna  4   5
Affiliations

Prognostic factors and treatment choice for stage IV, low-volume metastasis hormone-sensitive prostate cancer: cross-sectional study of real-world data

Mohamed Ibrahim Elewaily et al. Ther Adv Urol. .

Abstract

Background: Many metastatic prostate cancer prognostics have been suggested, but few are validated. Nodal metastasis burden and baseline biochemical characteristics are overlooked in the currently accepted stratifications for metastatic hormone-sensitive prostate cancer (mHSPC). Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) is likely to increase the incidence of pelvic nodal and mHSPC undetected by conventional scans. However, there is no consensus on managing regional nodal metastasis (N1M0) and no separate guidelines for non-regional nodal (M1a) and low-volume bone (M1b) spread but collectively as a part of low-volume CHAARTED disease.

Objectives: To assess the different prognostic factors for stage IV disease classified as CHAARTED low-volume on a real-world series of patients and to examine treatment preference for each of the disease subcategories.

Methods and design: This retrospective cross-sectional study included patients diagnosed with HSPC at stage IV, with low-volume disease according to the CHAARTED criteria. Data were collected from the database of Portsmouth and St. Mary NHS Hospitals between February 2017 and August 2023. Patient characteristics were analysed, and prognostic factors were evaluated using Cox regression analysis. 5-year progression-free survival (PFS) was the primary outcome measure.

Results: Data on 126 patients were analysed. Seven patients (6%) had N1M0, 28 (22%) M1a, and 91 (72%) M1b. 5-year PFS was 80.9% for M1a and 54.9% for M1b metastases, p = 0.3. High prostate-specific antigen (PSA) value (⩾25) was identified as an independent prognostic factor for PFS with HR = 2.80 (95% CI: 1.19-6.56), p = 0.0179. Variable treatment preference for each subclass reflects the uncertainty regarding the best regimen and the importance of consolidation prostate radiotherapy (cRT) in clinical practice.

Conclusion: Early results of our data analysis underscore the significance of baseline PSA as an independent prognostic factor alongside anatomical tumour extent of spread in stage IV low-volume metastasis prostate cancer. There is no agreement on treatment for each subcategory, necessitating further real-world studies and clinical trials. Further follow-up would assess the prognostic benefit of cRT.

Keywords: hormone-sensitive; low-volume prostate; metastatic prostate cancer; prognostic factors; real-world data; stage IV prostate.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest.

Figures

Figure 1.
Figure 1.
Progression-free survival stage IV low-volume mHSPC patients stratified by the metastatic site. mHSPC, metastatic hormone-sensitive prostate cancer.
Figure 2.
Figure 2.
Progression-free survival stage IV low-volume mHSPC patients stratified by the baseline PSA. mHSPC, metastatic hormone-sensitive prostate cancer; PSA, prostate-specific antigen.
See this image and copyright information in PMC

References

    1. Halabi S, Owzar K. The importance of identifying and validating prognostic factors in oncology. Semin Oncol 2010; 37(2): e9–e18. - PMC - PubMed
    1. Cornford P, van den Bergh RC, Briers E, et al.. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer—2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol 2024; 86: 148–163. - PubMed
    1. Buyyounouski MK, Choyke PL, McKenney JK, et al.. Prostate cancer–major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67(3): 245–253. - PMC - PubMed
    1. Napoli G, Arcangeli S, Fionda B, et al.. A systematic review and a meta-analysis of randomized controlled trials’ control groups in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). Curr Oncol Rep 2022; 24(11): 1633–1644. - PubMed
    1. Glass TR, Tangen CM, Crawford ED, et al.. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 2003; 169(1): 164–169. - PubMed

LinkOut - more resources